Predicted to enable RNA binding activity and splicing factor binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Predicted to be located in nucleus. Predicted to be part of U12-type spliceosomal complex; U2 snRNP; and U2-type precatalytic spliceosome. Biomarker of hepatocellular carcinoma. Human ortholog(s) of this gene implicated in Nager acrofacial dysostosis; cervical cancer; and hepatocellular carcinoma. Orthologous to human SF3B4 (splicing factor 3b subunit 4).
RGD Description
Predicted to enable RNA binding activity and splicing factor binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Predicted to act upstream of or within positive regulation of mRNA splicing, via spliceosome. Predicted to be located in nucleus. Predicted to be part of U12-type spliceosomal complex; U2 snRNP; and U2-type precatalytic spliceosome. Biomarker of hepatocellular carcinoma. Human ortholog(s) of this gene implicated in Nager acrofacial dysostosis; cervical cancer; and hepatocellular carcinoma. Orthologous to human SF3B4 (splicing factor 3b subunit 4); PARTICIPATES IN spliceosome pathway; INTERACTS WITH (+)-schisandrin B; 2,4-dinitrotoluene; 4-amino-2,6-dinitrotoluene.